Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36964
Title: | Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink | Authors: | Abtahi, Shahab Driessen, Johanna H. M. Burden, Andrea M. Souverein, Patrick C. VAN DEN BERGH, Joop van Staa, Tjeerd P. Boonen , Annelies de Vries , Frank |
Issue Date: | 2022 | Publisher: | OXFORD UNIV PRESS | Source: | RHEUMATOLOGY, 61 (4) , p. 1448-1458 | Abstract: | Objectives Clinical trials have shown that low-dose glucocorticoid therapy in patients with RA reduces bone loss in hands or hip, but the effect on osteoporotic fractures is not yet clear. Therefore, we investigated the use of low-dose oral glucocorticoids and risk of osteoporotic fractures among patients with RA. Methods This was a cohort study including patients with RA aged 50+ years from the Clinical Practice Research Datalink between 1997 and 2017. Exposure to oral glucocorticoids was stratified by the most recent prescription in current (<6 months), recent (7-12 months) and past (>1 year) use, and average daily and cumulative doses. Risk of incident osteoporotic fractures (including hip, vertebrae, humerus, forearm, pelvis and ribs) was estimated by time-dependent Cox proportional-hazards models, adjusted for lifestyle parameters, comorbidities and comedications. Secondary analyses assessed osteoporotic fracture risk with a combination of average daily and cumulative doses of oral glucocorticoids. Results Among 15 123 patients with RA (mean age 68.8 years, 68% females), 1640 osteoporotic fractures occurred. Current low-dose oral glucocorticoid therapy (<= 7.5 mg prednisolone equivalent dose/day) in patients with RA was not associated with overall risk of osteoporotic fractures (adjusted hazard ratio 1.14, 95% CI 0.98, 1.33) compared with past glucocorticoid use, but was associated with an increased risk of clinical vertebral fracture (adjusted hazard ratio 1.59, 95% CI 1.11, 2.29). Results remained unchanged regardless of a short-term or a long-term use of oral glucocorticoids. Conclusion Clinicians should be aware that even in RA patients who receive low daily glucocorticoid doses, the risk of clinical vertebral fracture is increased. | Notes: | Souverein, PC (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, POB 80082, NL-3508 TB Utrecht, Netherlands. p.c.souverein@uu.nl |
Keywords: | osteoporotic fractures;RA;glucocorticoids;BMD | Document URI: | http://hdl.handle.net/1942/36964 | ISSN: | 1462-0324 | e-ISSN: | 1462-0332 | DOI: | 10.1093/rheumatology/keab548 | ISI #: | WOS:000756404900001 | Rights: | The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, [br]distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
OP-BRHE210549 1448..1458.pdf | Published version | 410.13 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
18
checked on Oct 6, 2024
Page view(s)
38
checked on Sep 6, 2022
Download(s)
12
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.